Lung cancer is a formidable challenge in clinical practice owing to its metastatic nature and
resistance to conventional treatments. The codelivery of anticancer agents offers a potential …

Erlotinib-based EGFR targeted therapy has proven significant clinical improvement against
non-small cell lung cancer (NSCLC). However, the anticancer activity of Erlotinib (Ertb) is …

Aims: The aim of this study was to obtain adriamycin-loaded polymer–lipid hybrid
nanoparticles conjugated with anti-EGF receptor antibody (PLNP-Mal-EGFR) for …

Erlotinib (ERT), oral administration agents, is one of the most pivotal targeted drugs in the
treatment of non‐small cell lung cancer (NSCLC); however, its poor solubility, low oral …

Lung cancer is the leading cancer and has the highest death rate. The epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib has had a promising response …

Purpose Lung cancer is the leading cause of cancer mortality worldwide. Drug resistance is
the major barrier for the treatment of non-small cell lung cancer (NSCLC). The aim of this …

Cancer treatments are always associated with various challenges, and scientists are
constantly trying to find new therapies and methods. Erlotinib (ELT) is a well-known …

Aim: Hybrids composed of various materials are highly versatile for drug delivery in tumor
therapy including hepatocellular carcinoma. Herein, a sorafenib (SF)-loaded …

Erlotinib (ELT) as a small molecule with poor solubility, poor bioavailability, and instability in
gastrointestinal environment, has been considered as a therapeutic agent for Non-Small …

This study was aimed at developing a nanoparticle strategy to overcome acquired
resistance against erlotinib in non-small cell lung cancer (NSCLC). To load erlotinib on …